What is 89bio Price-to-Operating-Cash-Flow?
As of today (2024-05-31), 89bio's share price is $7.90.
89bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.70. Hence, 89bio's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for 89bio's Price-to-Operating-Cash-Flow or its related term are showing as below:
89bio's Cash Flow from Operations per share for the
three
months ended in Mar. 2024 was $-0.41.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.70.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 14.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 16.60% per year.
During the past 6 years, 89bio's highest 3-Year average Operating Cash Flow per Share Growth Rate was 40.10% per year. The lowest was -12.00% per year. And the median was 14.20% per year.
89bio Price-to-Operating-Cash-Flow Historical Data
The historical data trend for 89bio's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
89bio Price-to-Operating-Cash-Flow Chart
|
89bio Annual Data
|
|
Trend |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
- |
- |
- |
- |
- |
|
89bio Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of 89bio's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, 89bio's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
89bio's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 89bio's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where 89bio's Price-to-Operating-Cash-Flow falls into.
89bio Price-to-Operating-Cash-Flow Calculation
89bio's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 7.90 | / | -1.701 |
| = | |
89bio's Share Price of today is $7.90.
89bio's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.70.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
89bio (ETNB) Business Description
Traded in Other Exchanges
N/A
Address
142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Executives
| Kathleen Laporte |
director |
|
| Rohan Palekar |
director, officer: Chief Executive Officer |
201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
| Atkinson Edward Morrow Iii |
director |
C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104 |
| Quoc Le-nguyen |
officer: See Remarks |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Ryan Martins |
officer: Chief Financial Officer |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Michael R Hayden |
director |
C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
| Ra Capital Healthcare Fund Lp |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ra Capital Nexus Fund, L.p. |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Ram Waisbourd |
officer: See Remarks |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Orbimed Advisors Llc |
director, 10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Gregory Grunberg |
director, 10 percent owner |
100 BEAVER STREET, WALTHAM MA 02453 |
| Anat Naschitz |
director, 10 percent owner |
535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
| Longitude Capital Partners Iii, Llc |
10 percent owner |
800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
| Lota S. Zoth |
director |
334 CR 692, BUFFALO GAP TX 79508 |
| Steven Altschuler |
director |
MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ETNB has been successfully added to your